Neuregulin 1 Controls Glutamate Uptake by Up-regulating Excitatory Amino Acid Carrier 1 (EAAC1)*

Background: NRG1 and its receptor ErbB4 are schizophrenia susceptibility genes. Results: NRG1 induced the up-regulation of EAAC1 with an increase in glutamate uptake. Conclusion: NRG1/ErbB4 signaling influences glutamate uptake by increasing the EAAC1 protein level. Significance: These results contribute to understanding of a possible mechanism of NRG1/ErbB4 signaling that may be linked to the neural circuitry disruption in schizophrenia. Neuregulin 1 (NRG1) is a trophic factor that is thought to have important roles in the regulating brain circuitry. Recent studies suggest that NRG1 regulates synaptic transmission, although the precise mechanisms remain unknown. Here we report that NRG1 influences glutamate uptake by increasing the protein level of excitatory amino acid carrier (EAAC1). Our data indicate that NRG1 induced the up-regulation of EAAC1 in primary cortical neurons with an increase in glutamate uptake. These in vitro results were corroborated in the prefrontal cortex (PFC) of mice given NRG1. The stimulatory effect of NRG1 was blocked by inhibition of the NRG1 receptor ErbB4. The suppressed expression of ErbB4 by siRNA led to a decrease in the expression of EAAC1. In addition, the ablation of ErbB4 in parvalbumin (PV)-positive neurons in PV-ErbB4−/− mice suppressed EAAC1 expression. Taken together, our results show that NRG1 signaling through ErbB4 modulates EAAC1. These findings link proposed effectors in schizophrenia: NRG1/ErbB4 signaling perturbation, EAAC1 deficit, and neurotransmission dysfunction.

Neuregulin 1 (NRG1) is a trophic factor that is thought to have important roles in the regulating brain circuitry. Recent studies suggest that NRG1 regulates synaptic transmission, although the precise mechanisms remain unknown. Here we report that NRG1 influences glutamate uptake by increasing the protein level of excitatory amino acid carrier (EAAC1). Our data indicate that NRG1 induced the up-regulation of EAAC1 in primary cortical neurons with an increase in glutamate uptake. These in vitro results were corroborated in the prefrontal cortex (PFC) of mice given NRG1. The stimulatory effect of NRG1 was blocked by inhibition of the NRG1 receptor ErbB4. The suppressed expression of ErbB4 by siRNA led to a decrease in the expression of EAAC1. In addition, the ablation of ErbB4 in parvalbumin (PV)-positive neurons in PV-ErbB4 ؊/؊ mice suppressed EAAC1 expression. Taken together, our results show that NRG1 signaling through ErbB4 modulates EAAC1. These findings link proposed effectors in schizophrenia: NRG1/ErbB4 signaling perturbation, EAAC1 deficit, and neurotransmission dysfunction.
Neuregulin 1 (NRG1) 3 signaling proteins contain an epidermal growth factor (EGF)-like motif, which binds to and activates the ErbB receptor tyrosine kinase. NRG1 has multiple actions during synaptogenesis in the developing brain. Recent studies have clearly shown its role in the regulation of synaptic plasticity and neurotransmission (1). NRG1 acts to suppress the induction of long-term potentiation (LTP) (2,3) in the hippocampus (2)(3)(4)(5). In vitro studies have shown that NRG1 suppresses NMDA receptor-mediated currents in prefrontal cortex (PFC) neurons (6). NRG1 has also been shown to induce the internalization of surface AMPA receptors in hippocampal neurons (2). ErbB4 expression in the brain is mainly restricted to ␥-amino butyric acid (GABA) ergic interneurons (4,7). NRG1 has been shown to stimulate GABA release in PFC slices through the ErbB4 receptor (8). NRG1 suppresses LTP by enhancing GABA release. Interestingly, these effects require ErbB4 in parvalbumin (PV)-positive neurons (9). ErbB4 is located predominantly in the PV-positive interneurons (4,10) that contribute to regulate the neuronal network balance. Which synaptic molecules are linked with the NRG1-mediated regulation of neuronal activity remains unclear.
The concentrations of synaptic glutamate are tightly regulated by Na ϩ -dependent high affinity glutamate transporters that ensure crisp synaptic neurotransmission. This family consists of five members: GLAST, GLT-1, EAAC1, EAAT4, and EAAT5 (also known collectively as EAAT1-5). Excitatory amino acid carrier 1 (EAAC1) is a glutamate transporter present in the presynaptic pool, in opposition to two other main transporters, GLAST and GLT1, that are expressed at the excitatory amino acid synapse by surrounding astrocytes (11). EAAC1 is found throughout the brain on the somas and dendrites of small and large pyramidal neurons (12)(13)(14). EAAC1 is also localized to presynaptic GABA containing terminals and may have a metabolic role in providing glutamate for GABA metabolism (13,15). The loss of brain EAAC1 expression interferes with GABA synthesis and results in epilepsy (12,16). Moreover, EAAC1 expression is altered in pathological conditions, such as hypoxia/ischemia, multiple sclerosis, schizophrenia, and epilepsy (17). These findings suggest that EAAC1 may be important for the function or development of GABAergic metabolism and neurotransmission in the brain.
Our study demonstrates that NRG1/ErbB4 signaling influences glutamate uptake by regulating EAAC1 and suggests that this pathway can contribute to neurotransmission and to the etiology of schizophrenia. methoxy]-L-aspartic acid (TFB-TBOA) was from Tocris. DMSO was from Sigma. PV-ErbB4 mice and GAD (glutamic acid decarboxylase)-GFP mice were kindly provided by Prof. Lin Mei at Georgia Regents University (9). Experiments with animals were performed in accordance with institutional and Eulji University guidelines.

Experimental Procedures
Cell Culture-Primary cortical neurons were cultured essentially as described (8). Dissociated cortical neurons from E18 Sprague-Dawley rat embryos were cultured for 14 days after seeding (DIV) in Neurobasal medium supplemented with B27 (Gibco, Carlsbad, CA). Rat C6 glioma cells were obtained from the Korean cell line bank (Seoul, Korea) and grown in DMEM supplemented with 10% fetal bovine serum and a penicillinstreptomycin mixture.
RT-PCR and Quantitative Real-time PCR (qRT-PCR)-Total RNA was isolated from primary cortical neurons and C6 cells with TRIzol (Invitrogen). The following primers were used for PCR: slc1a1 (S), 5Ј-atgcttctgcctcgtctttggac-3Ј, (AS), 5Ј-atgcccagcgattaggaacaaaa-3Ј. All of the primers were designed with the help of primer 3 programs according to the known or predicted rat sequences reported in GenBank TM . qRT-PCR was performed using Bio-Rad Bio-Plex Systems with the DyNAmo SYBR Green qRT-PCR Kit (Finnzymes). For all of the probands, each cycle consisted of a denaturation step at 95°C for 10 s, followed by separate annealing (20 s) and extension (30 s) steps at a temperature characteristic for each proband. Fluorescence was monitored at the end of each extension step. The specificity of each PCR product was verified by performing dissociation reaction plots. Data were normalized to GAPDH. Real-time PCR data presented here had a p Ͻ 0.05 in Student's t test.
Western Blotting-Immunoblotting was performed as previously described (8). Samples were separated on a polyacrylamide gel and transferred to PVDF membranes. The membranes were blocked with TBS containing 0.05% Tween-20 and 5% skim milk. The blots were then reacted with primary antibodies overnight at 4°C and subsequently incubated using secondary antibodies conjugated with horseradish peroxidase and an enhanced chemiluminescent substrate (Amersham Biosciences Pharmacia).
Immunofluorescence-Immunostaining of ratprimary cortical neurons (E18, DIV14), C6 glioma cells, and brain sections were performed as described (8). Briefly, the cells were reacted in the blocking solution containing antibodies against ErbB4 In Vitro Glutamate Uptake Assay-Glutamate uptake was measured as described previously (18). After the cells were washed twice with uptake buffer (pH 7.4, 10 mM glucose, 5 mM KCl, 127 mM NaCl, 10 mM Hepes, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , and 1.3 mM KH 2 PO 4 ), glutamate uptake measurements were initiated by adding L -[ 3 H]glutamate (250 Ci/ mol, PerkinElmer Life Sciences, Boston, MA) at 5 M final concentration (4 M cold plus 1 M radioactive glutamate). L-Glutamate uptake was terminated after 2 min incubations at 37°C. The reaction was stopped by adding cold, sodium-free buffer. To dissolve the cells, 1 N NaOH was added to the culture dishes and the radioactivity was measured by a Liquid Scintillation Analyzer Tri-Carb 2900TR (PerkinElmer). The values of L -[ 3 H]glutamate incorporation were divided by protein content. Na ϩ -dependent uptake was calculated as the difference in radioactivity accumulated in the presence and absence of Na ϩ .
Biotinylation-The biotinylation assay was performed as described previously (18). In brief, cells were rinsed three times with ice-cold PBS containing 0.1 mM calcium and 1.0 mM magnesium (Ca/Mg PBS). The cells were then incubated with 1 mg/ml sulfo-NHS-SS-biotin in Ca/Mg PBS for 20 min at 4°C with gentle shaking. The unreacted biotin was removed, and the biotin was quenched using Ca/Mg PBS containing 100 mM glycine. The cells were lysed with RIPA buffer containing protease and phosphatase inhibitors. The lysates were centrifuged at 16,500 ϫ g for 30 min to remove cellular debris. Aliquots of the lysate were further incubated with an equal volume of a 50% slurry of avidin beads for 1 h and centrifuged at 16,500 ϫ g for 10 min at 4°C. SDS sample buffer was added to the cell lysate, biotinylated proteins (cell surface proteins), and non-biotinylated proteins (intracellular proteins). Each of these fractions was diluted and loaded so that the sum of immunoreactivity in the non-biotinylated and biotinylated fractions equaled the immunoreactivity in the lysate (if the yield from avidin extraction was 100%).
Intracerebroventricular (ICV) Infusion of NRG1 using an Osmotic Pump-The ICV infusion experiments were carried out with Alzet Micro-Osmotic Pumps (model 1004, DURECT, with a capacity of 100 l and at a pump rate of 0.11 l/h for 4 weeks) as described previously (19). The osmotic pumps were filled with NRG1 peptide (28 ng/kg) or PBS according to the manufacturer's instructions. A group of mice underwent ICV cannulation with the Alzet Brain Infusion kit (DURECT), and subcutaneous osmotic pumps were used to infuse into the right lateral ventricle of the brain. Mice were anesthetized via an intramuscular injection of Rompun (17.5 mg/kg) and Zoletil (12.5 mg/kg) and were sacrificed after infusion of NRG1 for 4-weeks. The mice were immediately intracardially perfused with PBS containing heparin. After perfusion, each brain was removed and stored at Ϫ70°C.
Statistical Analysis-The results are expressed as the mean Ϯ S.E. The differences between several groups were analyzed by one-way ANOVA followed by Bonferroni's post-hoc test. Comparisons between two groups were performed with Student's paired t test. Significance was accepted for a p value of Ͻ 0.05.

NRG1 Induces the Up-regulation of EAAC1-Several previ-
ous studies have shown that NRG1 signaling regulates neurotransmission (8). However, it is not clear how NRG1 signaling controls the GABA circuit. Because EAAC1 expression has been found on presynaptic GABA terminals (20,21), where the transporter is thought to supply glutamate as a precursor for GABA synthesis (11,16), we hypothesized that NRG1 signaling may be involved in the regulation of EAAC1. Based on this hypothesis, we investigated the effect of NRG1 on the regulation of glutamate transporters in C6 cells. EAAC1 represents the predominant glutamate transporter expressed by C6 cells, although the expression of GLT1 and GLAST is also detectable at very low levels in these cells (22). NRG1 showed no effect on the protein levels of the astroglial transporters (GLAST and GLT1); however, NRG1 treatment in C6 cells increased the neuronal transporter EAAC1. Moreover, this effect was shown in a concentration-dependent manner (Fig. 1, A and B). As shown in Fig. 1, C and D, NRG1 also up-regulated EAAC1 in primary cortical neurons.
To verify these results in vivo, we infused vehicle or NRG1 into the lateral ventricle of mice brains using an osmotic pump with a stereotaxic apparatus. Consistent with the in vitro result, NRG1 dramatically increased EAAC1 protein levels in PFC of NRG1-infused mice brain (Fig. 1, E and F). Treatment with 5 nM NRG1 showed a maximal response in 30 min; this dose was used for further experiments (Fig. 2, A and B).
The surface expression of EAAC1 is important for its function, so we investigated whether NRG1 affects the protein level of EAAC1 in the cell membrane by performing a biotinylation assay. NRG1 increased the surface expression of EAAC1 and increased the EAAC1 expression in total cell lysates (Fig. 2, C  and D). However, NRG1 increased not only the expression of surface EAAC1 but also the intracellular expression of EAAC1 (Fig. 2, E and F). These results indicate that NRG1 regulates EAAC1 expression in the brain without affecting the astroglial transporters, GLAST and GLT1.
ErbB4 Is Necessary for EAAC1 Up-regulation by NRG1-We investigated the possible role of ErbB receptors in the NRG1mediated regulation of EAAC1 expression. The cells were treated with AG1478 (an inhibitor of ErbB4) and AG879 (an inhibitor of ErbB2) (8). First, we confirmed that EAAC1, ErbB2, and ErbB4 were expressed in C6 cells (Fig. 3A). Treatment with AG1478 prevented NRG1 from up-regulating EAAC1 in C6 cells, but treatment with AG879 did not (Fig. 3, B and C).
In addition, we investigated whether ErbB4 was involved in the EAAC1 up-regulating effect of NRG1in primary cortical neurons. Similar to C6 cells, treatment with AG1478, prevented NRG1 from up-regulating EAAC1 in the cells (Fig. 3, D and E). We checked the mRNA level of EAAC1 by performing RT-PCR and qRT-PCR after treating C6 cells and primary cortical neurons with 5 nM NRG1. NRG1 did not affect the mRNA level of EAAC1 in the cells (Fig. 3, F and G). These data suggest that ErbB4 activation is required for NRG1-mediated regulation of EAAC1, whereas ErbB2 is not involved.
We performed immunocytochemistry to investigate EAAC1 immunoreactivity and localization in primary cortical neurons and found that NRG1 significantly increased EAAC1 immunoreactivity in comparison to control and that EAAC1 co-localized with ErbB4 in primary cortical neurons (Fig. 4, A and B).
NRG1 Increases Glutamate Uptake in Primary Cortical Neurons-To confirm that EAAC1 up-regulated by NRG1 is functional, we measured glutamate uptake in primary cortical neurons by employing a [ 3 H]glutamate in vitro uptake assay system. NRG1 treatment increased glutamate uptake in primary cortical neurons in a dose-dependent manner (Fig. 5A). To further investigate the involvement of EAAC1, we characterized the glutamate uptake assay by treatment with TFB-TBOA (a selective non-transportable EAAT inhibitor) at a concentration of 50 nM, which is known to block GLAST and GLT1 without affecting EAAC1 (23). In the presence of TFB-TBOA, the effect of NRG1 was not affected (Fig. 5B). Moreover, treatment with AG1478 prevented NRG1 from increasing glutamate uptake. In contrast, AG879 had no effect (Fig. 5C).
We performed immunocytochemistry to investigate EAAC1 immunoreactivity in C6 cells and found that ErbB4 siRNA significantly decreased EAAC1 immunoreactivity in comparison to control (Fig. 6, G and H). These observations confirm a role of endogenous ErbB4 in the NRG1-mediated up-regulation of EAAC1.
EAAC1 Is Remarkably Reduced in PV-ErbB4 Ϫ/Ϫ Mice-We checked the protein level of EAAC1 in PV-ErbB4 Ϫ/Ϫ mice to investigate the involvement of ErbB4 in vivo. ErbB4 is predominantly located in PV-positive interneurons (7,9,10,26). PV-ErbB4 Ϫ/Ϫ mice are PV-specific ErbB4 knock-out mice. In PV-Cre mice, the expression of Cre recombinase is activated at postnatal day 13 (27,28). As shown in Fig. 7, A and C, ErbB4 was reduced in the various brain areas. In addition, PV was also reduced in the brains of PV-ErbB4 Ϫ/Ϫ mice (Fig. 7, A and D), which is in agreement with previous studies (9), Importantly, EAAC1 was dramatically reduced but not GLT1 and GLAST in several brain regions (prefrontal cortex, cortex, hippocampus, and striatum) of PV-ErbB4 Ϫ/Ϫ mice ( Fig. 7, A-F).
EAAC1 was found to be remarkably reduced in same region of PV-ErbB4 Ϫ/Ϫ (Fig. 7, A and B), indicating that ErbB4 in PVpositive neurons is required for EAAC1 expression. In addition, we stained PFC sections of mice that express GFP in inhibitory neurons (GAD 67 mice, Jackson Lab) to examine the subcellular localization of EAAC1 in GABAergic neurons. EAAC1 immunoreactivity colocalized with GFP fluorescence when stained with either anti-mouse antibodies (Fig. 8, A and B). In total, 37% of GAD-GFP clusters were colocalized with EAAC1, and 72% of EAAC1 cluster was colocalized with GAD-GFP positive puncta-ring-like staining neurons in the PFC (Fig. 8, A and  B). These observations suggest that EAAC1 is expressing at presynaptic GABAergic neurons in the PFC.
In addition, we stained coronal sections of the PFC of control (PV-ErbB4 ϩ/ϩ ; top panels) and PV-ErbB4 Ϫ/Ϫ (bottom panels) mice with anti-PV and anti-EAAC1. In total, 48 and 78% of FIGURE 1. NRG1 up-regulates EAAC1 expression. A, C6 cells were treated with varying concentrations of NRG1 at 30 min and resulted in dose-dependent increases in EAAC1 expression. B, quantification of the data in A. n ϭ 6. *, p Ͻ 0.05; **, p Ͻ 0.01. C, dose-dependent increases in EAAC1 expression in primary cortical neuronal cells. D, quantification of the data in C. n ϭ 6. *, p Ͻ 0.05; **, p Ͻ 0.01. E, increased EAAC1 expression in PFC of NRG1-infused mice. Experimental scheme of the intraventricular infusion of the NRG1 peptide using an osmotic pump. NRG1 (28 ng/kg) or PBS was infused into 6-month-old mice. F, statistical analysis of the expression of EAAC1 in the PFC. n ϭ 4. **, p Ͻ 0.01. EAAC1 clusters colocalized with PV in the control and PV-ErbB4 Ϫ/Ϫ positive puncta-ring like staining neurons in the PFC, respectively (Fig. 8, C and D). On the other hand, the colocalization of PV clusters with EAAC1 did not significantly differ. However, EAAC1 immunoreactivity decreased in the PFC of the PV-ErbB4 Ϫ/Ϫ mice (Fig. 8E). These results indicate that the reduction in EAAC1 expression is not only observed in PV neurons but also in non-PV neurons. Taken together, these results indicate that ErbB4 expression in PV-positive interneurons may be critical for EAAC1 expression.

Discussion
A prominent hypotheses as to the underlying pathophysiology of schizophrenia is that disturbances in GABAergic and glutamatergic neurotransmission play causal factors. Patients with schizophrenia have been shown to have decreased expression of GAD 67 mRNA (29) and of the GABA transporter GAT-1 (30) in the PFC. The expression of PV is also reduced in the brains of schizophrenia patients (31). Accumulating evi-dence supports the action of NRG1/ErbB4 signaling as a stimulator of GABAergic transmission, which may contribute to compensating for abnormal GABAergic circuitry. In humans, reducing glutamatergic transmission can mimic schizophrenia (32), while enhancing glutamatergic transmission can alleviate symptoms (33). Patients with the disease show decreased excitatory synaptic function in hippocampal and cortical regions (34 -36). NRG1 functions by activating the ErbB family of tyrosine kinase receptors, including ErbB2, ErbB3, and ErbB4. ErbB2 cannot bind to NRG1 but forms an activated heterodimer with ErbB3 or ErbB4. ErbB3, and ErbB4 can bind to NRG1; in this case, ErbB4 homodimers take on the activating form, whereas ErbB3 is kinase-inactive (9). Recent studies have provided strong evidence that NRG1/ErbB4 signaling is a schizophrenia susceptibility pathway. NRG1/ErbB4 signaling is a schizophrenia susceptibility pathway. NRG1 and ErbB4 have been identified as candidate genes for schizophrenia (9). In animal models, mice lacking of NRG1, or ErbB gene cause various behavioral deficits including hyperactivity, prepulse inhibition (PPI), social behavior, and working memory (1,(37)(38)(39). In particular, the lack of ErbB4 in PV-positive neurons also showed schizophrenia-like behavioral abnormalities (9) similar to the traits exhibited by NRG1 or ErbB4 mutant mice. These genetic studies have suggested a link between NRG1/ErbB4 signaling and schizophrenia.
In the brain, glutamate serves as an excitatory neurotransmitter, a metabolic substrate for GABA, and as an amino acid for general cellular metabolism. Glutamate transporters maintain low extracellular glutamate and influence the kinetics of glutamate receptor activation. The function of EAAC1 in the CNS has not yet been established. Recent studies indicate that EAAC1 functions as a cysteine transporter, maintains neuronal glutathione metabolism and has a unique anti-apoptotic activity in injured neurons (40). Knock-out of EAAC1 in rodent leads to the development of epilepsy, resulting from the reduced synthesis of the neurotransmitter GABA (16), dicarboxylic aminoaciduria, and significant motor impairment (15). Changes in the glutamate transport activity of EAAC1 are associated with LTP and fear conditioning (41). Increased EAAC1 transcripts and proteins were reported in schizophrenic subjects (dorsolateral prefrontal and anterior cingulated cortex) (42). In contrast, decreased SLC1A1 transcript expression in the striatum was observed in schizophrenia (and in bipolar disorder) (43) and confirmed in patients with schizophrenia in a later study (44). This study provides evidence that EAAC1 may play an important role in synaptic plasticity, maintenance, or regulation. Despite advances in the field, a mechanism has not been identified that can link GABAergic and glutamatergic neurotransmission to NRG1 signaling.  (10, 20, 30, and 40 g). B, inhibition of NRG1 by AG1478 induced the increase of EAAC1 expression. C6 cells were pretreated without or with 5 M AG879 (ErbB2 inhibitor) and 5 M AG1478 (ErbB4 inhibitor) for 15 min prior to the addition of NRG1 (5 nM, final concentration) for 30 min. C, quantification analysis of data in B. n ϭ 6. *, p Ͻ 0.05. D, inhibition of ErbB4 blocks NRG1-induced increases of EAAC1 in primary cortical neurons. E, bar graph summarizes the data in D. n ϭ 6. *, p Ͻ 0.05. F, no effect of NRG1 was observed on mRNA levels of EAAC1 in C6 cells (n ϭ 6). G, qRT-PCR was performed to examine EAAC1 expression in cultured primary hippocampal neurons after treatment with 5 nM NRG1.
In this study, we investigated the function of NRG1 signaling in the regulation of neuronal glutamate transporters in the brain. The predominant neuronal glutamate transporter, EAAC1, may play a role in regulating GABA synthesis because glutamate is a precursor to GABA. We demonstrated that NRG1 regulates glutamate uptake by up-regulating EAAC1 in neuronal cells. NRG1 showed no effect on the protein level of astroglial transporters (GLAST and GLT1). These results provide a direct link between NRG1 and the glutamatergic system in neuronal cells. Inhibition of ErbB4 signaling by the specific ErbB4 inhibitor AG1478 or by knocking-down ErbB4 by siRNA prevented NRG1 from up-regulating EAAC1 expression and glutamate uptake in neuronal cells. Moreover, EAAC1 immunoreactivity was increased by NRG1 and colocalized with ErbB4 in primary cortical neurons. Therefore, we propose that NRG1 regulates EAAC1 by the direct activation of ErbB4 receptors. Altered NRG1-ErbB4 signaling is shown to contribute to NMDA hypofunction in schizophrenia (45)(46)(47). Based on the previous findings above, our findings support the notion that up-regulation of EAAC1 by NRG1 may provide a potential mechanism of glutamatergic hypofunction in schizophrenia.
We found an interesting relationship between ErbB4 and EAAC1 in PV-positive interneurons. The specific absence of ErbB4 in PV interneurons inhibited EAAC1 expression, indicating a crucial role of ErbB4 in PV-positive interneurons in the regulation of EAAC1 expression. EAAC1 is localized to the dendrite and soma of many neurons. Rare presynaptic localization is restricted to GABA terminals (16). A previous study found that ErbB4 is located in presynaptic GABAergic neurons in the PFC and that ErbB4 is mainly expressed in PV-positive interneurons, which are involved in neurotransmission and  synaptic plasticity (9). In accordance with these results, we found that EAAC1 was expressed in presynaptic GABAergic neurons, including PV-positive neurons in the PFC. The presence of EAAC1 in GAD-GFP-positive neurons and its colocalization with PV provides anatomical evidence that supports this notion. In addition, the ratio of PV-positive clusters co-expressed with EAAC1 was increased in the PFC of PV-ErbB4 Ϫ/Ϫ mice compared with controls, and EAAC1 immunoreactivity decreased in the PFC of PV-ErbB4 Ϫ/Ϫ mice. These results suggest that EAAC1 expression remained decreased in the remain-  ing PV clusters, which decreased in PV-ErbB4 Ϫ/Ϫ mice. However, a recent study has revealed that the spine density and the number of excitatory synapse are reduced in PV-ErbB4 Ϫ/Ϫ mice (47), which may contribute to the reduction in EAAC1 expression in the mouse model. Therefore, further study is required to determine whether it is a direct effect or whether it is an effect caused by the changes of synapse in PV-ErbB4 Ϫ/Ϫ mice. Nevertheless, we found that NRG1/ErbB4 signaling is critical to EAAC1 expression and function. More work is required to determine the mechanism of protein levels and transport activity through NRG1/ErbB4 signaling.
In conclusion, our results reveal a novel function of NRG1/ ErbB4 in the modulation of EAAC1 expression and function. These results suggest that the regulation of EAAC1 by NRG1 may participate in normal GABA or glutamate transmission and that the alterations in EAAC1 may also contribute to the GABAergic or glutamatergic dysfunction implicated in schizophrenia. These results contribute to a better understanding of how abnormal NRG1/ErbB4 signaling may be involved in the pathogenesis of schizophrenia.